The present disclosure relates to crystalline morphic forms of 4-amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide. The morphic form can be a stable hemihydrate crystalline form.
本公开涉及 4-
氨基-7-((2R,3R,4S,5R)-3,4-二羟基-5-(羟甲基)
四氢呋喃-2-基)-2-甲基-7H-
吡咯并[2,3-d]
嘧啶-5-甲酰胺的结晶形态。形态形式可以是稳定的半
水结晶形式。